Advanced search
Publication Cover
mAbs Volume 15, 2023 - Issue 1
Submit an article Journal homepage
2,626
Views
0
CrossRef citations to date
0
Altmetric
Report

Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer

Jiawei Guana Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), China;b Savaid Medical School, University of Chinese Academy of Sciences, Beijing, ChinaView further author information
,
Hongchuan Liuc Department of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co Ltd, Shanghai, ChinaView further author information
,
Yan Chaia Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), ChinaView further author information
,
Jie Yud Pilot National Laboratory for Marine Science and Technology (Qingdao), Shandong, ChinaView further author information
,
Jian Yaoc Department of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co Ltd, Shanghai, ChinaView further author information
,
Jing Wangc Department of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co Ltd, Shanghai, ChinaView further author information
,
Zhiwei Panc Department of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co Ltd, Shanghai, ChinaView further author information
,
Jing Zhangc Department of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co Ltd, Shanghai, ChinaView further author information
,
Yuehua Zhouc Department of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co Ltd, Shanghai, ChinaView further author information
,
Hui Liuc Department of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co Ltd, Shanghai, ChinaView further author information
,
Sheng Yaoc Department of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co Ltd, Shanghai, ChinaView further author information
,
Jianxun Qia Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), ChinaView further author information
,
Hui Fengc Department of Antibody Discovery and Engineering, Shanghai Junshi Biosciences Co Ltd, Shanghai, ChinaView further author information
,
George F. Gaoa Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), China;b Savaid Medical School, University of Chinese Academy of Sciences, Beijing, ChinaView further author information
,
Qihui Wanga Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), China;b Savaid Medical School, University of Chinese Academy of Sciences, Beijing, ChinaCorrespondence[email protected]
[email protected]
[email protected]
View further author information
,
Yi Shia Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), China;b Savaid Medical School, University of Chinese Academy of Sciences, Beijing, ChinaView further author information
&
Shuguang Tana Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), China;b Savaid Medical School, University of Chinese Academy of Sciences, Beijing, ChinaORCID Iconhttps://orcid.org/0000-0002-2599-4959View further author information
ORCID Icon show all
Article: 2153409 | Received 03 Aug 2022, Accepted 26 Nov 2022, Published online: 13 Dec 2022

References

  • Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–11. doi:10.1126/science.aaa8172. PMID: 25838373
  • Tan S, Gao GF. New hope for cancer treatment: cancer immunotherapy. Chin Sci Bull. 2015;60:3155–57. in Chinese.
  • Tan S, Chen D, Liu K, He M, Song H, Shi Y, Liu J, Zhang CW, Qi J, Yan J, et al. Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell. 2016;7(12):866–77. PMID: 27815822. doi:10.1007/s13238-016-0337-7.
  • Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol. 1998;18(5):389–418. doi:10.1615/critrevimmunol.v18.i5.10. PMID: 9784967
  • Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600–03. PMID: 21474713. doi:10.1126/science.1202947.
  • Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. PMID: 20525992. doi:10.1056/NEJMoa1003466.
  • Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015;3(4):301–09. PMID: 25819643. doi:10.1016/S2213-2600(15)00092-2.
  • Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, et al. Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. Clin Exp Immunol. 2019;197(1):74–82. PMID: 30821848. doi:10.1111/cei.13283.
  • Calabrò L, Rossi G, Morra A, Rosati C, Cutaia O, Daffinà MG, Altomonte M, Di Giacomo AM, Casula M, Fazio C, et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir Med. 2021;9(9):969–76. PMID: 33844995. doi:10.1016/S2213-2600(21)00043-6.
  • Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma. N Engl J Med. 2015;373(1):23–34. PMID: 26027431. doi:10.1056/NEJMoa1504030.
  • Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015;194(3):950–59. PMID: 25539810. doi:10.4049/jimmunol.1401686.
  • Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33. PMID: 23724867. doi:10.1056/NEJMoa1302369.
  • Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. PMID: 25891173. doi:10.1056/NEJMoa1503093.
  • Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46. PMID: 31562797. doi:10.1056/NEJMoa1910836.
  • Du X, Liu M, Su J, Zhang P, Tang F, Ye P, Devenport M, Wang X, Zhang Y, Liu Y, et al. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. Cell Res. 2018;28(4):433–47. PMID: 29463898. doi:10.1038/s41422-018-0012-z.
  • Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31. PMID: 31562796. doi:10.1056/NEJMoa1910231.
  • Du X, Tang F, Liu M, Su J, Zhang Y, Wu W, Devenport M, Lazarski CA, Zhang P, Wang X, et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res. 2018;28(4):416–32. PMID: 29472691. doi:10.1038/s41422-018-0011-0.
  • Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, Fields JK, Sundberg EJ, Latinovic OS, Devenport M, et al. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res. 2019;29(8):609–27. PMID: 31267017. doi:10.1038/s41422-019-0184-1.
  • Gao H, Cai H, Liu J, Wang X, Zheng P, Devenport M, Xu T, Dou F, Liu Y, Zhou A. Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody. Cell Discov. 2020;6(1):79. doi:10.1038/s41421-020-00202-9. PMID: 33298884
  • He M, Chai Y, Qi J, Zhang CWH, Tong Z, Shi Y, Yan J, Tan S, Gao GF. Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget. 2017;8(40):67129–39. doi:10.18632/oncotarget.18004. PMID: 28978021
  • Lee JY, Lee HT, Shin W, Chae J, Choi J, Kim SH, Lim H, Won Heo T, Park KY, Lee YJ, et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun. 2016;7(1):13354. PMID: 27796306. doi:10.1038/ncomms13354.
  • Liu H, Bi X, Zhou Y, Shi R, Yao S, Qi J, Feng H, Feng M, Yan J, Tan S. Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy. Signal Transduct Target Ther. 2020;5(1):158. doi:10.1038/s41392-020-00254-z. PMID: 32839442
  • Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, Stahl ML, Seehra J, Somers WS, Mosyak L. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature. 2001;410(6828):608–11. doi:10.1038/35069118. PMID: 11279502
  • Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature. 2001;410(6828):604–08. doi:10.1038/35069112. PMID: 11279501
  • Ramagopal UA, Liu W, Garrett-Thomson SC, Bonanno JB, Yan Q, Srinivasan M, Wong SC, Bell A, Mankikar S, Rangan VS, et al. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proc Natl Acad Sci U S A. 2017;114(21):E4223–E4232. PMID: 28484017. doi:10.1073/pnas.1617941114.
  • Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, et al. Fc effector function contributes to the activity of human anti-ctla-4 antibodies. Cancer Cell. 2018;33(4):649–663.e4. PMID: 29576375. doi:10.1016/j.ccell.2018.02.010.
  • Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–26.
  • Read RJ. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr. 1997;276:307–26. PMID: 27754618. doi:10.1016/S0076-6879(97)76066-X.
  • Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60:2126–32. doi: 10.1107/S0907444904019158. PMID: 15572765. 12
  • Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66(2):213–21. PMID: 20124702. doi:10.1107/S0907444909052925.
  • Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 1):12–21. doi:10.1107/S0907444909042073. PMID: 20057044

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.